Efficacy and safety of camrelizumab plus famitinib in patients with previously treated non-small-cell lung cancer: a single-arm, phase II trial

Background: For non-small-cell lung cancer (NSCLC) patients who progressed after first-line chemotherapy, immunotherapy targeting programmed cell death (ligand) 1 has shown promising activity. However, the activity is relatively limited in patients harboring epidermal growth factor receptor (EGFR) m...

Full description

Saved in:
Bibliographic Details
Main Authors: Ming Gao, Xia Zhang, Huan Yan, Yan Zhao, Fang Yuan, Decong Sun, Xuejiao Yang, Yanfang Ju, Lijie Wang, Haitao Tao, Luyuan Tian, Changhong Zhao, Junxun Ma, Yi Hu, Zhefeng Liu
Format: Article
Language:English
Published: SAGE Publishing 2025-01-01
Series:Therapeutic Advances in Medical Oncology
Online Access:https://doi.org/10.1177/17588359241311058
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1846095880855224320
author Ming Gao
Xia Zhang
Huan Yan
Yan Zhao
Fang Yuan
Decong Sun
Xuejiao Yang
Yanfang Ju
Lijie Wang
Haitao Tao
Luyuan Tian
Changhong Zhao
Junxun Ma
Yi Hu
Zhefeng Liu
author_facet Ming Gao
Xia Zhang
Huan Yan
Yan Zhao
Fang Yuan
Decong Sun
Xuejiao Yang
Yanfang Ju
Lijie Wang
Haitao Tao
Luyuan Tian
Changhong Zhao
Junxun Ma
Yi Hu
Zhefeng Liu
author_sort Ming Gao
collection DOAJ
description Background: For non-small-cell lung cancer (NSCLC) patients who progressed after first-line chemotherapy, immunotherapy targeting programmed cell death (ligand) 1 has shown promising activity. However, the activity is relatively limited in patients harboring epidermal growth factor receptor (EGFR) mutations. Objectives: This study aimed to evaluate the efficacy and safety of camrelizumab plus famitinib in previously treated patients with locally advanced and metastatic NSCLC. Design: A single-center, single-arm, phase II study. Methods: Previously treated patients with locally advanced and metastatic NSCLC were enrolled to receive camrelizumab (200 mg, administered intravenously every 3 weeks) and famitinib (20 mg, administered orally once daily). Patients harboring EGFR mutation genes had received at least one EGFR tyrosine kinase inhibitor and no more than two lines of chemotherapy regimen before the enrollment. The other patients had progressed on first-line chemotherapy with or without immunotherapy before the enrollment. The primary endpoint was the objective response rate (ORR) per RECIST v1.1 by the investigator. Results: Our study encompassed 23 NSCLC patients between October 2019 and October 2022. For all patients, the confirmed ORR was 30.4%, and the disease control rate was 95.7%. The median progression-free survival (PFS) was 6.9 months (95% CI: 4.9 months–not reached). The median overall survival (OS) was not reached. 1- and 2-year OS rates were 85.6% (95% CI: 71.8%–100.0%) and 56.8% (95% CI: 37.7%–85.7%). Especially, for the 6 patients with EGFR genetic aberrations, the confirmed ORR was 33.3%, the median PFS was 10.3 months (95% CI: 1.8–18.8 months), and the median OS was 20.3 months (95% CI: 0.8–39.8 months). The most common grade 3 and above treatment-related adverse events were platelet count decreased, white blood cell count decreased, and hypertension. No unexpected adverse events were reported. Conclusion: Camrelizumab plus famitinib demonstrated encouraging clinical activity with a manageable safety profile in previously treated patients with locally advanced and metastatic NSCLC. The results warranted further validation. Trial registration: Chinese Clinical Trial Registry identifier: ChiCTR1900026641.
format Article
id doaj-art-a48f52d9223d48c8b9a06a9273b2c6c4
institution Kabale University
issn 1758-8359
language English
publishDate 2025-01-01
publisher SAGE Publishing
record_format Article
series Therapeutic Advances in Medical Oncology
spelling doaj-art-a48f52d9223d48c8b9a06a9273b2c6c42025-01-02T09:03:23ZengSAGE PublishingTherapeutic Advances in Medical Oncology1758-83592025-01-011710.1177/17588359241311058Efficacy and safety of camrelizumab plus famitinib in patients with previously treated non-small-cell lung cancer: a single-arm, phase II trialMing GaoXia ZhangHuan YanYan ZhaoFang YuanDecong SunXuejiao YangYanfang JuLijie WangHaitao TaoLuyuan TianChanghong ZhaoJunxun MaYi HuZhefeng LiuBackground: For non-small-cell lung cancer (NSCLC) patients who progressed after first-line chemotherapy, immunotherapy targeting programmed cell death (ligand) 1 has shown promising activity. However, the activity is relatively limited in patients harboring epidermal growth factor receptor (EGFR) mutations. Objectives: This study aimed to evaluate the efficacy and safety of camrelizumab plus famitinib in previously treated patients with locally advanced and metastatic NSCLC. Design: A single-center, single-arm, phase II study. Methods: Previously treated patients with locally advanced and metastatic NSCLC were enrolled to receive camrelizumab (200 mg, administered intravenously every 3 weeks) and famitinib (20 mg, administered orally once daily). Patients harboring EGFR mutation genes had received at least one EGFR tyrosine kinase inhibitor and no more than two lines of chemotherapy regimen before the enrollment. The other patients had progressed on first-line chemotherapy with or without immunotherapy before the enrollment. The primary endpoint was the objective response rate (ORR) per RECIST v1.1 by the investigator. Results: Our study encompassed 23 NSCLC patients between October 2019 and October 2022. For all patients, the confirmed ORR was 30.4%, and the disease control rate was 95.7%. The median progression-free survival (PFS) was 6.9 months (95% CI: 4.9 months–not reached). The median overall survival (OS) was not reached. 1- and 2-year OS rates were 85.6% (95% CI: 71.8%–100.0%) and 56.8% (95% CI: 37.7%–85.7%). Especially, for the 6 patients with EGFR genetic aberrations, the confirmed ORR was 33.3%, the median PFS was 10.3 months (95% CI: 1.8–18.8 months), and the median OS was 20.3 months (95% CI: 0.8–39.8 months). The most common grade 3 and above treatment-related adverse events were platelet count decreased, white blood cell count decreased, and hypertension. No unexpected adverse events were reported. Conclusion: Camrelizumab plus famitinib demonstrated encouraging clinical activity with a manageable safety profile in previously treated patients with locally advanced and metastatic NSCLC. The results warranted further validation. Trial registration: Chinese Clinical Trial Registry identifier: ChiCTR1900026641.https://doi.org/10.1177/17588359241311058
spellingShingle Ming Gao
Xia Zhang
Huan Yan
Yan Zhao
Fang Yuan
Decong Sun
Xuejiao Yang
Yanfang Ju
Lijie Wang
Haitao Tao
Luyuan Tian
Changhong Zhao
Junxun Ma
Yi Hu
Zhefeng Liu
Efficacy and safety of camrelizumab plus famitinib in patients with previously treated non-small-cell lung cancer: a single-arm, phase II trial
Therapeutic Advances in Medical Oncology
title Efficacy and safety of camrelizumab plus famitinib in patients with previously treated non-small-cell lung cancer: a single-arm, phase II trial
title_full Efficacy and safety of camrelizumab plus famitinib in patients with previously treated non-small-cell lung cancer: a single-arm, phase II trial
title_fullStr Efficacy and safety of camrelizumab plus famitinib in patients with previously treated non-small-cell lung cancer: a single-arm, phase II trial
title_full_unstemmed Efficacy and safety of camrelizumab plus famitinib in patients with previously treated non-small-cell lung cancer: a single-arm, phase II trial
title_short Efficacy and safety of camrelizumab plus famitinib in patients with previously treated non-small-cell lung cancer: a single-arm, phase II trial
title_sort efficacy and safety of camrelizumab plus famitinib in patients with previously treated non small cell lung cancer a single arm phase ii trial
url https://doi.org/10.1177/17588359241311058
work_keys_str_mv AT minggao efficacyandsafetyofcamrelizumabplusfamitinibinpatientswithpreviouslytreatednonsmallcelllungcancerasinglearmphaseiitrial
AT xiazhang efficacyandsafetyofcamrelizumabplusfamitinibinpatientswithpreviouslytreatednonsmallcelllungcancerasinglearmphaseiitrial
AT huanyan efficacyandsafetyofcamrelizumabplusfamitinibinpatientswithpreviouslytreatednonsmallcelllungcancerasinglearmphaseiitrial
AT yanzhao efficacyandsafetyofcamrelizumabplusfamitinibinpatientswithpreviouslytreatednonsmallcelllungcancerasinglearmphaseiitrial
AT fangyuan efficacyandsafetyofcamrelizumabplusfamitinibinpatientswithpreviouslytreatednonsmallcelllungcancerasinglearmphaseiitrial
AT decongsun efficacyandsafetyofcamrelizumabplusfamitinibinpatientswithpreviouslytreatednonsmallcelllungcancerasinglearmphaseiitrial
AT xuejiaoyang efficacyandsafetyofcamrelizumabplusfamitinibinpatientswithpreviouslytreatednonsmallcelllungcancerasinglearmphaseiitrial
AT yanfangju efficacyandsafetyofcamrelizumabplusfamitinibinpatientswithpreviouslytreatednonsmallcelllungcancerasinglearmphaseiitrial
AT lijiewang efficacyandsafetyofcamrelizumabplusfamitinibinpatientswithpreviouslytreatednonsmallcelllungcancerasinglearmphaseiitrial
AT haitaotao efficacyandsafetyofcamrelizumabplusfamitinibinpatientswithpreviouslytreatednonsmallcelllungcancerasinglearmphaseiitrial
AT luyuantian efficacyandsafetyofcamrelizumabplusfamitinibinpatientswithpreviouslytreatednonsmallcelllungcancerasinglearmphaseiitrial
AT changhongzhao efficacyandsafetyofcamrelizumabplusfamitinibinpatientswithpreviouslytreatednonsmallcelllungcancerasinglearmphaseiitrial
AT junxunma efficacyandsafetyofcamrelizumabplusfamitinibinpatientswithpreviouslytreatednonsmallcelllungcancerasinglearmphaseiitrial
AT yihu efficacyandsafetyofcamrelizumabplusfamitinibinpatientswithpreviouslytreatednonsmallcelllungcancerasinglearmphaseiitrial
AT zhefengliu efficacyandsafetyofcamrelizumabplusfamitinibinpatientswithpreviouslytreatednonsmallcelllungcancerasinglearmphaseiitrial